Metoject (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA and RNA synthesis. This action reduces the proliferation of immune cells and malignant cells, providing anti‑inflammatory effects in arthritis and psoriasis and cytotoxic effects in certain cancers.

The specific dose and dosing schedule of Metoject are determined by the prescribing clinician based on the individual’s condition, weight, renal and hepatic function, and treatment response. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Metoject is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as methotrexate can be excreted in breast milk and may affect the infant. Effective contraception is required during treatment.

To request Metoject, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Metoject is a subcutaneous formulation of methotrexate, offering rapid absorption and consistent bioavailability compared with oral tablets, which can have variable absorption. This route may be preferred for patients who need higher systemic exposure or who experience gastrointestinal side effects with oral dosing.

Metoject should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Do not store at room temperature for extended periods, as stability may be compromised.

Metoject is given by subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a healthcare professional or a trained patient using aseptic technique. The exact injection site, volume and frequency are prescribed by the treating clinician.

Serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening bone‑marrow suppression, acute kidney injury, and severe infections. Patients should be monitored regularly with liver function tests, pulmonary assessments, renal function checks and complete blood counts to detect early signs of toxicity.

Metoject should not be used by pregnant individuals, those with severe renal or hepatic impairment, patients with known hypersensitivity to methotrexate, or individuals receiving live vaccines. It is also contraindicated in patients with uncontrolled infections or pre‑existing severe bone‑marrow disorders.